Plus   Neg

Keep An Eye On These Biotech Stocks This Month, If Invested


The clinical trials can make or break drug companies as their stock price reaction can either be overwhelmingly positive or brutal depending upon the trial results.

A majority of the companies that have reported trial results so far this month have not disappointed their investors.

For example, Insmed Inc. (INSM) surged as much as 140% on September 5, 2017, following positive data from its phase III rare lung disease drug study. So did NewLink Genetics Corp. (NLNK) after reporting updated results from a mid-stage study of its lead candidate, Indoximod, in melanoma patients, climb more than 85% on September 5, 2017, and further added 33% the following day.

Kura Oncology Inc. (KURA) jumped more than 100% on September 8, 2017, helped by positive results from its mid-stage study of HRAS mutant head and neck cancer drug, called Tipifarnib.

But that's not all.

Aldeyra Therapeutics Inc.(ALDX), Halozyme Therapeutics Inc.(HALO) and Voyager Therapeutics Inc.(VYGR) are some of the other stocks that have made notable gains on the heels of positive trial results this month.

Now, let's take a look at the biotech companies that are expectedto report clinical trial resultsduring the remainder of this month.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT